Therapeutische antilichamen voor ernstige auto-immuunziektes en kanker











### rward Looking Statements




IS PRESENTATION HAS BEEN PREPARED BY ARGENX SE ("ARGENX" OR THE "COMPANY") FOR INFORMATIONAL PURPOSES ONLY AND NOT FOR ANY OTHER PURPOSE. NOTHING CONTAINED IN THIS ESENTATION IS, OR SHOULD BE CONSTRUED AS, A RECOMMENDATION, PROMISE OR REPRESENTATION BY THE PRESENTER OR THE COMPANY OR ANY DIRECTOR, EMPLOYEE, AGENT, OR ADVISER OF THE MPANY. THIS PRESENTATION DOES NOT PURPORT TO BE ALL-INCLUSIVE OR TO CONTAIN ALL OF THE INFORMATION YOU MAY DESIRE. THIS PRESENTATION ALSO CONTAINS ESTIMATES AND OTHER STATISTICAL TA MADE BY INDEPENDENT PARTIES AND BY US RELATING TO MARKET SIZE AND GROWTH AND OTHER DATA ABOUT OUR INDUSTRY. THIS DATA INVOLVES A NUMBER OF ASSUMPTIONS AND LIMITATIONS, AND U ARE CAUTIONED NOT TO GIVE UNDUE WEIGHT TO SUCH ESTIMATES.

e Harbor: Certain statements contained in this presentation, other than present and historical facts and ditions independently verifiable at the date hereof, may constitute forward-looking statements. mples of such forward-looking statements include those regarding our investigational product didates and preclinical studies and clinical trials, and the status, plans, timing of expected data readouts related presentations and related results thereof, including the design of our trials and the availability data from them, the timing and achievement of our product candidate development activities, future ults of operations and financial positions, including potential milestones, business strategy, plans and objectives for future operations. When used in this presentation, the words "anticipate," "believe," n," "could," "estimate," "expect," "intend," "is designed to," "may," "might," "will," "plan," "potential," edict," "objective," "should," or the negative of these and similar expressions identify forward-looking tements. Such statements, based as they are on the current analysis and expectations of management, erently involve numerous risks and uncertainties, known and unknown, many of which are beyond the pany's control. Such risks include, but are not limited to: the impact of general economic conditions, eral conditions in the biopharmaceutical industries, changes in the global and regional regulatory ironments in the jurisdictions in which the Company does or plans to do business, market volatility, tuations in costs and changes to the competitive environment. Consequently, actual future results may er materially from the anticipated results expressed in the forward-looking statements. In the case of ward-looking statements regarding investigational product candidates and continuing further elopment efforts, specific risks which could cause actual results to differ materially from the Company's rent analysis and expectations include: failure to demonstrate the safety, tolerability and efficacy of our duct candidates; final and quality controlled verification of data and the related analyses; the expense and uncertainty of obtaining regulatory approval, including from the U.S. Food and Drug Administration and European Medicines Agency; the possibility of having to conduct additional clinical trials; our ability to obtain and maintain intellectual property protection for our product candidates; and our reliance on third parties such as our licensors and collaboration partners regarding our suite of technologies and product candidates. Further, even if regulatory approval is obtained, biopharmaceutical products are generally subject to stringent on-going governmental regulation, challenges in gaining market acceptance and competition. These statements are also subject to a number of material risks and uncertainties that are described in the Company's filings with the U.S. Securities and Exchange Commission ("SEC"), including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. The reader should not place undue reliance on any forward-looking statements included in this presentation. These statements speak only as of the date made and the Company is under no obligation and disavows any obligation to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation.

## **Efgartigmod ITP Fase 2 Topline Data**

# argen

#### Veilig & duidelijk klinisch effect




- Innovative Access Program: 7 live programma's
- Additionele programma's oa:
  - ARGX-111 (c-MET vaste en bloed kankers) klaar om te partneren
  - ARGX-109 (IL-6 rheumatoid arthritis) gepartnered met Genor Biopharma

## Financiering van \$300M

argen

Efgartigimod: Fase 3 ITP, Fase 2 subcutane formulatie & 4<sup>de</sup> indicatie (CIDP)



- Innovative Access Program: 7 live programma's
- Additionele programma's oa:
  - ARGX-111 (c-MET vaste en bloed kankers) klaar om te partneren
  - ARGX-109 (IL-6 rheumatoid arthritis) gepartnered met Genor Biopharma



